New cell therapy start-up based on Simrit Parmar's research

19 September 2016

Hong Kong-listed Chinese healthcare firm Golden Meditech Holdings (SEHK: 00801) and The University of Texas at MD Anderson Cancer Center have announced the creation of Cellenkos, a start-up focused on umbilical cord blood derived T-regulatory (T-reg) cellular therapies.

Cellenkos, to be based in Houston, is funded with an initial investment of $10 million, with warrants to purchase a further $10 million worth of shares by Golden Meditech and an independent strategic investor.

The agreement covers technologies arising from the laboratory investigations of Simrit Parmar, associate professor in the Department of Stem Cell Transplantation and Cellular Therapy at MD Anderson.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK